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Summary 
This work describes the functional characterization, cDNA cloning, and expression of a novel 
cell surface protein. This protein designated gClq-R, was first isolated from Raji cells and was 
found to bind to the globular "heads" of Clq molecules, at physiological ionic strength, and 
also to inhibit complement-mediated lysis of sheep erythrocytes by human serum. The NHz- 
terminal amino acid sequence of the first 24 residues of the Clq-binding protein was determined 
and this information allowed the synthesis of two degenerate polymerase chain reaction primers 
for use in the preparation of a probe in the screening of a B cell cDNA library  The cDNA 
isolated,  using this probe, was found to encode a pre-pro protein of 282 residues.  The NH2 
terminus of the protein isolated from Raji cells started at residue 74 of the predicted pre-pro 
sequence. The cDNA sequence shows that the purified protein has three potential N-glycosylation 
residues and is a highly charged, acidic molecule. Hence, its binding to Clq may be primarily 
but not exclusively due to ionic interactions. The "mature" protein, corresponding to amino 
acid residues 74-282 of the predicted pre-pro sequence, was overexpressed in Escherichia coli and 
was purified to homogeneity This recombinant protein was also able to inhibit the complement- 
mediated lysis of sheep erythrocytes by human serum and was shown to be a tetramer by gd 
filtration in nondissociating conditions. Northern blot and RT-PCR studies showed that the 
Clq-binding protein is expressed at high levels in Raji and Dandi cell lines, at moderate levels 
in U937, Molt-4, and HepG2 cell lines, and at a very low level in the HL60 call line. However, 
it is not expressed in the K562 cell line. Comparison of gClq-R NHz-terminal sequence with 
that of the receptor for the collagen-like domain ofClq (cClq-R) showed no similarity. Furthermore, 
antibodies to gClq-R or an 18-amino acid residue-long NHz-terminal synthetic gClq-R peptide 
did not cross-react with antibodies to cClq-R. Anti-gClq-R immunoblotted a 33-kD Raft cell 
membrane protein, whereas anti cClq-R recognized a molecule of ,v60 kD. The NH2-terminal 
sequence of gClg-R appears to be displayed extracdlularly since anti-gClg-R peptide reacted 
with surface molecules on lymphocytes, polymorphonudear leukocytes, and platelets, as assessed 
by flow cytometric and confocal laser scanning microscopic analyses. In addition, all or part of 
the gClq binding domain may reside within the 24 amino acid stretch of the NHz-terminal 
sequence of gClq-R since the 18 amino acid residue long-synthetic peptide corresponding to 
this region inhibited serum Clq hemolytic activity The data presented in this report suggest 
that there are at least two types of Clq-R which appear to be expressed on the same type of 
ceils and these receptors individually or in concert may contribute to the diversity of Clq-mediated 
responses. 
C  lq binds to a variety of cells such as B cells, monocytes, 
macrophages, neutrophils, eosinophils, fibroblasts, plate- 
lets, endothelial and smooth muscle cells (1-9).  The biolog- 
ical responses elicited by Clq are also as diverse as the cell 
types that express the receptor (1). It enhances FcR- and CR1- 
mediated phagocytosis in monocytes and macrophages (10, 
11), stimulates Ig production by B cells (12, 13), activates 
platelets to express otIIb//33 integrins, P-selectin, and proco- 
agulant activity (14), and plays a role in the activation of tumor 
cytotoxidty of macrophages (15, 16). 
Most of the above actions of Clq are considered to be medi- 
ated by a Clq receptor that binds to the collagen-like regions 
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protein with a molecular mass of",'60 kD (1). However, this 
receptor has a rehtivdy low affinity to the collagen-like regions 
of Clq and binds at a very low ionic strength (10 mM potas- 
sium phosphate buffer) (17). In 1989, a high affinity receptor, 
which binds to the globular heads of Clq, was reported to 
be present, along with the low ai~nity receptor, on human 
diploid fibroblasts (18), thereby indicating that at least two 
types of Clq receptors might be involved to impart the vast 
array of Clq-mediated biologic functions. 
In this paper and in a previous report (19), a cell surface 
protein, which has a high affanity for the Clq globular heads, 
has been characterized. By the use of NHz-terminal protein 
sequence information  and PCR  techniques,  a  full-length 
cDNA done was isolated and the primary sequence of this 
protein has been predicted. Northern blot and RT-PCR studies 
were carried out to demonstrate the different levels of ex- 
pression of this protein in different cell lines.  Moreover, a 
recombinant form of this protein has been produced in Esch- 
erichia coli and  shown to be able to inhibit  complement- 
mediated lysis of sheep erythrocytes by human serum. 
Materiah and Methods 
Chemicals and Reagents 
The following chemicals and reagents were purchased from the 
sources indicated: FCS (Hydone Laboratories, Logan, UT); RPMI 
1640, 100x  antibiotic-antimycotic mixture (GIBCO BILL, Gai- 
thersburg, MD); Emulphogene BC 720 (polyoxyethylene-10  tridecyl 
ether),  FITC-conjugated  goat  anti-rabbit  IgG,  KLH,  DMSO 
(Sigma Chemical Co., St. Louis, MO); NHS-LC-biotin (Sulfosuc- 
cinirnidyl-6-[biotinamido] Hexanoate),  ImmunoPure A/G  IgG 
purification kit, ImmunoPure horseradish peroxidase-conjugated 
goat anti-rabbit IgG, 4-chloro-l-naphthol, Tween 20 (Pierce, Rock- 
ford, IL); Con A- Sepharose PD-10 cohmns (Pharmacia, Biotech, 
Inc., Uppsah, Sweden); Mono-Q, TSKgd DEAE-NPK cohmns 
(TosoHaas, Montgomeryville, PA); mI-Na (Amersham, Aylesbury, 
UK); and polyvinylidene diiluoride (PVDF) membranes, (Immo- 
bilon-P; Millipore Corp.,  Bedford, MA), 
Cultured Cells 
Raji cells were used to prepare membrane proteins and were 
grown in R.PMI 1640 containing 10% (vol/vol) heat-inactivated 
(3 h, 56~  FCS and 1% (vol/vol) ofa 100x antibiotic-antimycotic 
mixture that consisted of 10,000 U/ml penicillin G, 25/~g/ml am- 
photericin B, and 100,000/~g/ml streptomycin sulfate and main- 
rained in an atmosphere of 95% air and 5% CO2. When large 
quantities of Raji cells  were required, the cells  were grown in 2-liter 
roller bottles as described  earlier (20). Other cell lines such as Dandi, 
U937, Molt-4, and HL60 were grown under similar conditions. 
Purified Proteins 
Human Clq used in these studies was purified by the method 
of Reid (21). For comparison, Clq was also purified from a pool 
of freshly obtained sera according to the procedures of Yonemasu 
and Stroud (22) followed by purification on Con A-Sepharose 4B 
as described (23). 
The collagen "stalks" of Clq (cClq) were prepared by pepsin 
digestion of the purified Clq molecule following the procedure 
of Reid (24) and the globular "heads" of Clq were prepared by 
collagenase digestion as described (25). 
Radioiodination 
Except for Clq, which was labeled by the method of Bolton 
and Hunter (26), all other proteins were radiolabeled by the Io- 
dogen method (27) with 1 mCi of Nal'~I as described elsewhere 
(3, 28). After labeling, the free mI was removed by gel filtration 
using PD-10 (Sephadex G-25) columns equilibrated with the ap- 
propriate buffer system in which the labeled protein was to be kept. 
Purification of r 
The purification of Clq-R in these studies used a combination 
of two published methods (2, 3) with some minor modifications. 
These methods were: (a) alfinity purification on Clq-Sepharose 
CL-4B, (b) ion-exchange separation on FPLC using a Mono-Q 
column, and (c) HPLC purification using a TSKgel DEAE-NPR 
column as &scribed (3, 28). 
Clq--Sepharose Affinity  Chromatography.  Raji cell membranes 
were prepared from 20-1iter cultures (4  x  10  ~~ cells) as described 
in detail earlier (2, 20). Half of the solubilized membrane solution 
was then applied to a column packed with 3 ml of Clq-Sepharose 
Cb4B (3 mg Clq/ml Sepharose)  equilibrated with 10 mM sodium 
phosphate, pH 7.4, containing 20 mM NaCI, 0.1% Emulphogene 
BC720, and a cocktail of enzyme inhibitors (2, 20). After washing 
(5 x  cohnm volume), the bound proteins were eluted with the 
same buffer containing 1 M NaC1. The eluted material was dia- 
lyzed against equilibrating buffer, and a 0.5-ml aliquot was radio- 
labeled and then tested for Clq-binding  activity by a solid phase 
radioligand binding  assay described below. Preliminary studies 
showed that the eluted material contained most of the Clq-binding 
activity 
FPLC on Mono-Q Column.  The Clq-binding material eluted 
from the Clq-Sepharose  CL4B column was mixed with 100 td 
('~106 cpm) of the radiohbded sample and applied to a  1-ml 
Mono-Q colunm (9, 17). The column was washed until cpm/ml 
gl00, and then the bound proteins were eluted with a linear NaCI 
concentration gradient (0--600 mM NaC1). Clq-containing  frac- 
tions were identified  by solid phase  binding assay  (see  below), pooled, 
and concentrated. 
HPLC on DEAF. Column.  The concentrated, Clq-binding frac- 
tion from the Mono-Q cohnm was dialyzed against 50 mM Tris, 
pH 8.0, and then subjected to HPLC using a 1-ml TSK gel DEAE- 
NPR column as described (9, 17). The bound proteins were eluted 
using first a 0-500-mM NaCI gradient in equilibrating buffer (10 
min) and then a 500 mM-1 M gradient (3 min). 
Solid Phase Binding Assay 
Sofid phase radioligand assays were performed using lzsI-hbeled 
Clq-R  or Clq-R-enriched material by a  previously described 
method (20, 29). Briefly, 50/zl, 5/~g/ml each (15 raM NazCO3, 
35 mM NaHCO3,  pH 9.6) of Clq, cClq, or gClq were applied 
to duplicate  wells of fiat-bottomed strip phte-8 (Costar Corp., Cam- 
bridge, MA) and incubated for 2 h at 37~  Wells coated with 
either 1%, BSA, 100/~g/ml IgG, or 100/~g/ml properdin, served 
as irrelevant or positively charged protein controls. After incuba- 
tion, the wells were washed (3 x 300/~1) with TBST (50 mM "fi'is- 
HC1, pH 7.5, containing 150 mM NaC1 and 0.05% Tween 20). 
Then 50/~1 of mI-labeled Clq-R in TBB (20 mM Tris-HCl, pH 
7.5, containing 100/~g/rrd BSA) containing a fixed or increasing 
amounts of counts per minute were added and further incubated 
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wells washed (5 x 300 td) with "rBB, dried by tapping over a stack 
of filter papers, and the individual wells counted in a 3,-counter. 
SDS-PAGE and Western Blot Analysis 
SDS-PAGE analysis was performed on 1.5-mm-thick slab gels 
according to the method of  Laemmli  (30). Samples  were either run 
unreduced or reduced and alkyhted by boiling for 5 min in the 
presence of 0.1 M dithiothreitol and 0.2 M iodoacetamide. After 
running, the gels were stained with Coomassie Brilliant Blue, de- 
stained and dried. Gels containing radiolabeled samples were ex- 
posed to Kodak X-OMAT AR film at  -800C and then analyzed 
by autoradiography. Samples for Western blot analysis (31) were 
first run on SDS-PAGE, then electrotransferred  to polyvinyl  difluo- 
ride (PVDF) nitrocellulose membranes, blocked with 5% nonfat 
milk  containing  TBST, and  the bound proteins probed with 
predetermined dilutions of rabbit antibodies in the above buffer. 
The bound  antibodies were  visualized by horseradish peroxi- 
dase-conjugated goat anti-rabbit  IgG followed by reaction with 
4-chloro-l-naphthol substrate. 
NHrtenninal Amino Acid Sequencing and Peptide Synthesis 
The NH2-terminal sequence information of gClq-R was gener- 
ated using a protein sequencer and analyzer  (models 470A and 120A; 
Applied Biosystems,  Inc., Foster City, CA) as described elsewhere 
(28, 32). An 18-amino acid  residue-long synthetic peptide (gClq- 
Rts) derived from the NH2-terminal sequence of gClq-K was syn- 
thesized, on a peptide synthesizer  (model  430A; Applied Biosystems, 
Inc.) at the Center for Analysis and Synthesis of Macromolecules 
(Department of Medicine, State University of New York, Stony 
Brook, NY).  The peptide was then purified by gel filtration on 
HPLC. 
Antibody Production 
Antibody to gClq-R was prepared in rabbits according to the 
following schedule. Purified gClq-R (10-20/~g) in 200/~1 PBS 
was mixed with 200/tl each of complete and IFA and injected at 
three sites: one subcutaneous and two intramuscular. Booster in- 
jection was given as above 2 wk later and, thereafter, injections 
were made every 2 wk in IFA until a total of four such injections 
were made. The rabbits were then rested for 4-6 wk before a final 
injection was given and the rabbits bled and the serum collected 
and tested by ELISA against purified gClq-K. 
Antibody to gClq-R peptide was generated by injection of 500 
/~g of KLH-conjugated peptide following the immunization pro- 
tocol described above. Conjugation of gClq-K peptide to KLH 
was accomplished  by the glutaraldehyde  method as described (33). 
The IgG fraction from each antiserum was prepared using the Im- 
munoPure A/G IgG purification kit following the manufacturer's 
recommendations (Pierce). Antipeptide antibodies were further 
purified by affanity  purification on KLH-Sepharose CL4B. 
/zl GVB (Veronal-buffered saline, pH 7.4, containing 0.15 mM 
CaC12, 1 mM MgCh, and 0.1% gelatin). At the end of the incu- 
bation, the volume of the reaction mixtures was brought to 950 
#1 GVK and 50 #1 of EA (10Vml, sheep erythrocytes [E] sensi- 
tized with IgM anti-sheep E [A]) was added and further incubated 
for 60 rain at 370C. The reaction was then stopped, immediately 
centrifuged, and free hemoglobin in the supernatant assessed spec- 
trophotometrically at 412 nm. 
Confocal Laser Scanning Microscopy 
PBL, monocytes, and PMN were purified by a combination of 
Hcoll-HyFaque  sedimentation  (to separate  PMNs from mononuclear 
cells) and plastic adherence  in autologous serum (to separate mono- 
cytes from lymphocytes), as described  (34). For confocal  hser scan- 
ning microscopic (CLSM) analyses,  the celh were suspended  at 106 
celh/0.3 ml GVB (veronal-buffered  saline,  pH 7.4, containing 0.1% 
gelatin, 0.02% NAN3, and 5 ttg/ml cytochalasin  B), preincubated 
for 30 min at 4"C with a 1:5 dilution of Clq-depleted and heat- 
inactivated (56"C, 30 min) human serum to block Fc-K sites, and 
then incubated (1 h, 37"C or 40C) with 50/zl of a I mg/rrd each 
of either IgG anti gClq-K or IgG from preimmtme rabbit serum. 
After incubation, the cells were washed (2 x 2 ral) with cold GVB 
by centrifugation (800 g, 4"C), the pellet resuspended in 0.3 ml 
GVB and further incubated (1 h, 37"C or 4"C) with an appro- 
priate dilution of  HTC-conjugated goat anti-rabbit antibody. The 
cells were then washed (3 x 2 ml) in GVB resuspended  in original 
volume and analyzed by CLSM. 
cDNA  Cloning and Overexpression of gClq-R 
Generation of the First Strand eDNA from Raft Cell Total RNA 
by AMV Reverse Transcriptase. After purification  of  the Clq-binding 
protein, the sequence of the 24 NH2-terminal amino acids was de- 
termined by automated protein sequencing (Table I). Based  on this 
peptide, two degenerate PCK primers (BH-S and BH-3) (Table 2) 
were designed  and synthesized  on a DNA synthesizer  (modal 38LA; 
Applied Biosystems,  Cheshire, UK). The antisense primer (BH-3) 
was used as the primer for the first strand cDNA synthesis from 
total RNA. All the components in the reverse transcription reac- 
tion were from a kit (cDNA Synthesis System Plus; Amersham 
International, Amersham, Bucks, UK), except for total KNA and 
primer. In a 10-#1 reaction: 3.0 ttl HzO; 2.0/A 5x  first strand 
reaction buffer; 0.5 #1 sodium pyrophosphate  solution;  0.5 p,l gNase 
inhibitor; 1.0/~1 deoxynudeoside triphosphate mix; 1.0/zl BH-3 
primer (1/tg/rrd),  2.0/A Raji cell total RNA (10/~g/ttl); and 10 
U AMV reverse transcriptase were mixed together. After incuba- 
tion at 420C for 40 min, the tube was stored at -200C for subse- 
quent PCK amplification. 
Table  1.  Comparison  of the NH2-terminal Sequence of 
Raft cC1q-R and gCIq-R 
Hemolytic Assays 
The effect of gClq-R18, KLH-gClq-R18, or the soluble, recom- 
binant form of gClq-R (rgClq-R) was assessed  by incubating var- 
ious amounts of these molecules with 10/~1 normal human serum 
(NHS)  1 for 60 min at room temperature in a total volume of 100 
R~torty~  NH2-termin~sequence 
cClq-R  EPAVYFKEQFLDGDG 
gClq-R  LHTDGDKAFVDFLSDEIKEE  RKIQ 
1  Abbreviations used in  this paper: CLSM, confocal laser scanning 
microscopy; IFrG, isopropyl fl-D-thiogalactopyranoside;  NHS, normal 
human serum. 
The underlined sequence in gClq-R was used for the construction of 
two degenerate  oligonucleotide  probes as well as the generation  of a syn- 
thetic peptide (gClq-RlS). 
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Name  Sequence (5' -'~ 3')  Direction  Position 
BH-S  5'-AC I GAYGG I GAYAARGC I TT  Sense  a.a. 76-82 
BH-3  5'-YTG I ATYTT I CKYTCYTC  Antisense  a.a. 92-97 
KS-1  5'-CAGGAATTCCTGAGTGATGAAATTAAGG  Sense  ntd. 331-352 
KA-1  5'-TGGAATTCCATCACTCAGGAAATCAACA  Antisense  ntd. 324-343 
KS-2  5'-AACCCTCGCAAGGGCAGAA  Sense  ntd.  521-539 
BM-1  5'-GTAGGATTTGTTCACTGGCCA  Antisense  ntd. 967-988 
BN-1  5'-GCCATGGCTCTGCACACCGACGGAGAC  Sense  ntd.  297-315 
Fl1  5'-ACTCCTGGAGCCCGTCAGTAT  ~,gt  11 primer 
Rll  5'-GACCAACTGGTAATGGTAGCGAC  Xgt11 primer 
Added restriction sites are underlined: EcoRI(KS-1 and KA-1); Ncol(BN-1). 
a.a., amino acid; I, Inosine; ntd., nucleotide;  R, A/G; Y, C/T. 
Generation of the First Exact Match Oligonucleotide Probe by PCR 
Purification.  The first strand cDNA generated as described above 
was used as template and the two degenerate, inosine-containing 
oligonucleotides  (BH-S and BH-3) were used as primers in the PCR 
reaction. A PCR reaction was performed with 30 cycles  in a DNA 
thermal cycler (Perkin-Elmer/Cetus, Norwalk, CT) using a cycle 
of  denaturation for 0.5 rain at 94~  annealing  for 0.5 rain at 48~ 
and an extension at 72~  for 0.5 min. The reaction mixture (50 
#1) contained 25 pmol of each primer, 0.25 mM dNTP, 1.25 U 
Taq polymerase  (Promega, Southampton, OK) with the manufac- 
turer's buffer system, together with 1.0/~1 first strand cDNA. The 
PCR product (5/~1) was ehctrophoresed on a 4% (wt/vol) agarose 
gd (Nusieve; FMC Bioproducts Europe, Vagensbaek, Denmark). 
The expected 66-bp product was obtained. 
Subcloning and DNA Sequencing.  After electrophoresis,  the 66-bp 
fragment was cut out from the gel and extracted from the gel slice 
by centrifugation through glass wool (35). The DNA fragment 
(6/~1 of  duant) was bkmtend-ligated  to the HincII site ofpBluescript 
SK (0.1/~g) using T4 DNA ligase (1 U, Amersham) in a 10-#1 
reaction volume overnight at room temperature. The E. coli strain 
XI.-Blue 1 was used as the host in the transformation of cells with 
the ligation mixture. After transformation, the cells were plated 
on LAT plates (LB plates with 100/~g/ml ampicillin and 10/~g/ml 
tetracycline), which had been spread with X-Gal and isopropyl-B- 
D-thiogalactopyranoside  (IFIG) several hours before the cells were 
inoculated. White colonies were screened by the PCR using the 
T7 and T3 primers and conditions as used previously Colonies 
that yielded  the 246-bp PCR product (a 180-bp fragment was gener- 
ated if there is no insert) were selected  and the phsmids were purified 
by alkaline lysis method from a 10-ml miniprep culture. Double- 
stranded DNA sequencing  was performed on two purified plasmids 
by the dideoxynucleotide chain termination procedure using T7 
polymerase (Pharmacia). 
Screening of the ~ gt 11 Human B Cell cDNA Library.  Two oli- 
gonucleotide probes (KS-1 and KA-1, Table 2) were synthesized 
based on the DNA sequence of the clones generated by PCR. An 
EcoR1 site was added at the 5' end of each probe. These oligonu- 
cleotides were endlabeled  with [3Zp]ATP using T4 kinase and were 
used to screen the library (,~106 plaques, Clonetech, Palo Alto, 
CA) separately,  with KS-1 being used for first screening and KA-1 
for second screening. Positive  plaques  were picked  up and the phages 
were resuspended in 1 ml SM buffer (50 mM Tris-HC1, 10 mM 
NaC1, 10 mM MgSO4, and 0.01% gelatin). Screening of the posi- 
tive plaques was performed by PCR reactions with primers KS-1 
and the primers Fll or Rll in 25-/~1 reaction volumes. Fll (left 
arm) and Rll (right arm) were vector-specific primers. Cultures 
(10 ml) were grown from four positive plaques and )~ DNA was 
isohted by X mini kit (Qiagen Hybaid Ltd., Middlesex,  OK). EcogI 
inserts were released by digestion, with EcoRI purified and sub- 
cloned into pBlueseript for sequence analysis.  Three cDNA clones 
of 1.0-1.1 kb were sequenced by the dideoxynucleotide chain ter- 
mination procedure using T7 polymerase. 
Subcloning the eDNA Insert Encoding the gC1q-R into Plasmid  pGex. 
2T.  First, a NcoI site was created in the pGex-2T plasmid (36). 
pGex-2T plasmid  was digested  by Sinai, desphosphorylated  by alka- 
line phosphatase, and ligated to a NcoI linker (10 met) by T4 DNA 
ligase. Plasmid  (pGex-2TN) with the NcoI site inserted  was selected, 
cultured, and purified by alkaline lysis method. Second, in order 
to create a NcoI site on the gClq-R protein insert for subdoning, 
a PCIL primer (BN-1) was synthesized. A 50-/~1 PCR reaction was 
carried out using BN-1 and T7P (a pBluescript primer) as primers 
andpBhescript containing the gClq-R eDNA insert as a temphte. 
PFU DNA polymerase (Promega) was used to rephce Taq poly- 
merase so as to secure a high fidelity. The amplified  PCIL product 
was then precipitated and digested by NcoI  and BamH1. The 
digested insert was purified by gel and subcloned into the NcoI 
site and BamHI site of pGex-2TN. The phsmid that contained 
the right insert was isolated (pGex-2TNH) and transformed into 
E. coli strain NM554. 
~pression  of CIq-binding Protein (Residues 74-282 of the Amino 
Acid Sequence Predicted  from the cDNA  Clone) in E. coli Employing 
pGex-2T Vector.  A colony carrying pGex-2TNH was inoculated 
to a 100-ml LA (LB plus 50 mg/liter Ampicillin) and grown over- 
night at 37~  The next morning, the 100-ml culture was inocu- 
lated into 900 ml LA. After 1 h at 37~  protein expression was 
induced by 0.1 ram IIrI'G, the culture allowed to grow for 7 h 
at 37~  and the ceU harvested by centrifugation at 5,000 g for 
15 min. For every  liter of  culture, 15 ml MTPBSN (150 mM NaCI, 
16 mM NazI-IPO4, 4 mM NaHzPO~, 0.05% NAN3, 0.1% Triton 
X-100, pH 7.3) was used to resuspend the cell pellet. The cells 
were lysed by sonication (3 x  1 min) and the supernatant gener- 
ated by centrifugation at 12,000 g for 15 min contained soluble 
proteins, including GST-gClq-R fusion product. Glutathione aga- 
rose beads (5 ml, sulphur linkage; Sigma Chemical Co.) were pre- 
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buffer. The supematant  was allowed to pass through a column (10 
mm  x  150 ram) of the beads and the eluant was discarded. The 
column was washed by 50 ml MTPBSN to elute nonbinding pro- 
teius.  The fusion protein  was eluted  by competition  with free 
glutathione  using 20 ml 50 mM Tris-HCl, pH 8.0, containing  5 
mM reduced ghtathione (Sigma Chemical Co.) (final pH 7.5, freshly 
prepared). The ehent (20 ml) was made 150 mM with respect to 
NaC1 and 2.5 mM with CaClz before thrombin digestion.  The 
concentration  of the fusion protein at this stage was estimated to 
be 1.6 mg/ml. Thrombin was added to a concentration of 3.2/zg/ml 
and the digestion was allowed to proceed at room temperature for 
2 h on a rotating platform.  Complete digestion was achieved, as 
judged by SDS-PAGE carded out after reduction of disulfide bonds. 
A Mono-Q column (Pharmacia) was employed to purify the recom- 
binant protein. The pH of the sample was adjusted by adding one- 
twentieth the volume of I M Tris, pH 8.6. The sample was applied 
to a Mono-Q column (1 ml) preeqnilibrated in buffer A (20 mM 
Tris, pH 8.5, 0.05% sodium azide) at a flow rate of 0.5 ml/min. 
A large peak which was not retained on the column, was collected 
and then the column was washed with buffer A containing 0.4 M 
NaC1 until the base line returned to zero. Another peak was eluted 
by buffer A containing 0.6 M NaCI. The two peaks were run on 
a 15% (wt/vol) SDS-PAGE under reducing conditions and the band 
giving the expected sequence of the gClq-R protein  was deter- 
mined,  by NHz-terminal  peptide  sequencing  to be in the peak 
eluted with buffer A containing  0.6 M NaC1. 
Gel Filtration Chromatography.  The recombinant protein and the 
markers were dialyzed into the gel filtration running buffer (50 
mM Tris-HCl,  150 mM NaC1, 0.05% (wt/vol) NAN3, pH 7.5) 
and then loaded onto a Superose 12 column, which was connected 
to a FPLC system (Pharmacia). The molecular size markers em- 
ployed were bovine IgG (160 kD), OVA (43 kD), soybean trypsin 
inhibitor  (20.3 kD), and cytochrome C  (12.4 kD). 
Purification of Total RNA and Northern Blot Analysis.  Total  RNA 
(10/~g) from each sample was electrophoresed on a formaldehyde- 
containing 1% (wt/vol) agarose gel. After electrophoresis, the RNA 
was transferred to a Hybond-N membrane (Amersham) by capil- 
lary blotting and fixed onto the membrane by UV cross-linking 
(XL-1500 UV crosslinker; Spectronics Corporation, AMS, Burford, 
UK). A high specific  activity, single strand DNA probe was gener- 
ated by using the PCK method, with a 1.0-kb cDNA done as 
a template and the antisense primer, BM-1, using 30 cycles  of denatu- 
ration for 0.5 min at 94~  annealing for 0.5 min at 53~  and 
an extension at 72~  for 0.5 min. The reaction mixture (50/zl) 
contained 25 pmol of the primer, 0.2 mM cold dATP, dTTP, and 
dGTP, 0.625 U Taq polymerase (Promega) with the manufacturer's 
buffer system, together with 2/zl tx-[a2p]dCTP (3,000 Ci/mmole, 
10 mCi/ml). 
After labeling, the probe was purified on a nick column (Phar- 
macia) and added directly to the formamide containing prehybridi- 
zation buffer. The membrane was hybridized with the probe over- 
night at 42~  After hybridization,  the filter was washed three 
times with 2x  SSC, 0.1%  SDS at room temperature,  and then 
washed once in 0.1x  SSC, 0.1%  SDS at 65~  for 15 rain.  The 
filter was exposed to x-ray film for 7 d at  -70~ 
RT-PCR.  First strand cDNA from various cell lines was gener- 
ated from total RNAs and AMV reverse transcriptase as discussed 
above, except that oligo dT was used as primer. The first strand 
cDNAs were used as templates and the two oligonudeotides (KS-2 
and BM-1) were used as primers in the PCR reaction. PCR reac- 
tions were performed with 30 cycles of denaturation  for 0.5 min 
at 94~  annealing for 0.5 min at 53~  and an extension at 72~ 
for 45 s. The reaction mixture (50 #1) contained 25 pmol of each 
primer, 0.25 mM dNTP, 1.25 U Taq polymerase with the manufac- 
turer's buffer system, together with 1.0/~1 first strand cDNA. The 
PCR product (5/zl) was dectrophoresed on a 2% (wt/vol) NuSieve 
agarose gel. 
Results 
Purification  and  Characterization of gC1q-R  from  Raji 
Cells.  The  purification  of  gClqoR  used  sequentially, 
Clq-Sepharose CL-4B affinity chromatography (2), followed 
by FPLC on Mono-Q and then HPLC using a column of 
TSK gel DEAE-NPR (28, 32). When the Clqobinding frac- 
tion  from  the  FPLC  Mono-Q  column  was  subjected  to 
purification on HPLC, the profile depicted in Fig. 1 was ob- 
tained. Fractions duting between 9 and 18 min were coated 
onto microtiter plates and tested for their ability to bind lz~I- 
Clq by the solid phase radioligand binding assay. Three major 
regions  of activity were observed with  the  strongest  Clq 
binding noted with fractions corresponding to peak 4. The 
position where the RO-SS/A-associated calreticulin  is expected 
to dute is marked in Fig.  1 and is close to the position of 
cClq-R which duted at "~450 mM NaC1 (peak 1). Both of 
these molecules possess Clq-binding  activity. To assess the 
structure and composition of the molecules contained within 
this region of Clq-binding activity, 250-#1 samples were taken 
from each region and analyzed by SDS-PAGE and autoradi- 
ography. As shown in the composite autoradiogram  (inset, 
Fig. 1), peak 1 (inset A) contained a band of ~60 kD (non- 
reduced),  which  corresponds  to  the  molecular  weight  of 
cClq-R; peak 2 (inset B) contained a 60-kD band and an ad- 
ditional  80-kD band;  peak 3 (inset C) contained predomi- 
nantly the 80-kD band (nortreduced) whereas peak 4 (inset 
D) consisted of a single band that migrated with an apparent 
molecular mass of 33 kD. Solid phase binding studies per- 
formed on the 33-kD molecule showed that it binds to Clq 
very strongly in a dose-dependent and saturable manner (Fig. 
2). Although the binding of this molecule to Clq is enhanced 
by low ionic strength conditions, significant binding (70%, 
n  =  3) does occur even at physiologic ionic strength.  Fur- 
thermore,  whereas the binding of cClq-R and calreticulin 
to whole Clq was indistinguishable  from each other,  the 
binding of the 33-kD molecule was in general, two to three 
times higher than either the cClq-R or calreticulin (Fig. 2). 
In addition, both the 60- and 80-kD species in peak 2 (Fig. 
1) appeared to bind to Clq as assessed by autoradiographic 
analysis of these proteins after elution from Clq-coated mi- 
crotiter plates  (data not  shown). 
The 33-kD Molecule Binds to Globular Heads of Clq.  To 
identify the domain of Clq to which the 33-kD molecule 
binds, solid phase binding studies were performed by binding 
lz~I-33 kD to microtiter plate wells coated with Clq, cClq, 
gClq,  or BSA as described in Materials  and Methods.  As 
shown in Fig. 3, the 33-kD molecule binds with high affinity 
to  Clq  and  gClq  but  not  to cClq,  suggesting  that  it  is 
a unique molecule with preferential binding to the globular 
heads  of Clq.  Because its  elution  position  on  the  HPLC 
1813  Ghebrehiwet  et al. Figure 1.  HPLC  profile  of Clq-K purification.  Solubilized  Raji cell  membranes  were  sequentially  subjected  to purification  on Clq-Sepharose  Cb4B 
and FPLC Mono-Q. Fractions  containing  Clq-binding activity  were pooled and purified  on HPLC using TSK gel DEAE-NPR column  and proteins 
were eluted  using concentration  gradients  of 0-500 mM NaC1 (10 rain) and 500 mM-1 M (3 rain). The positions of cClq-R, which ehited  at ,,0450 
mM NaC1 and gClq-R which eluted at about 700 mM NaCI are indicated. (Inset) SDS-PAGE  analysis  of HPLC peaks. Samples  from major peaks 
(I-4) of HPLC were radiolabeled  and analyzed  by a 10% SDS-PAGE  (with [+], or without [-] reduction)  and autoradiography.  Lanes: (A) HPLC 
peak 1, contains  cClq-R; (/3) HPLC peak 2; (C) peak 3; and (D) HPI.C peak 4, shows a single  chain 33-kD gClq-K. 
suggests this molecule to be highly acidic,  an experiment 
was performed to demonstrate that the binding of this mol- 
ecule to  Clq,  a basic protein,  was not charge dependent. 
To this end, two very basic proteins,  human IgG and pro- 
perdin, were included in the binding assay and the binding 
of 12SI-gClq-R  to  these molecules compared with that of 
Clq and gClq. The result of a representative experiment (n  = 
3) is depicted in Fig.  4  and shows that lzSI-gClq-R binds 
to Clq and gClq but not to BSA, IgG, or properdin. Fur- 
thermore, gClq-R binds to Clq whose collagen stalks have 
been occupied by specific anti-stalks IgG (anti-cClq), whereas 
no binding was observed to IgG anti-cClq alone (Fig.  4). 
The  NH2-terminal Sequence of gCIq-R  Is Not  Similar to 
that of cClq-R.  To determine if the NH2-terminal amino 
acid  sequence of gClq-R  shows  any relationship  to  that 
of cClq-R., both molecules (i.e., peaks 1 and 4, Fig. 1) were 
subjected to  NHz-terminal  amino  add  sequence analyses. 
The results presented in Table  1 show that the two mole- 
cules do not appear to be related. Furthermore, within the 
24 amino acid residues of the 33-kD gClq-R there are four 
aspartic acid and three glutamine acid residues suggestive of 
its acidic nature. 
The NH2-terrainal Sequence of  gClq-R Contains gC1q-Binding 
Activity.  In an effort to raise antipeptide antibody for affinity 
purification and immunochemical studies, an 18 amino acid 
residue-long  synthetic peptide  (gClq-Kls)  of gClq-R  in 
Table 1 (underlined), was synthesized and purified on HPLC. 
Since a  preliminary study  had  indicated that  the Peptide 
binds to Clq  (data not  shown) it prompted the question: 
Does this peptide inhibit the hemolytic activity of Clq in 
serum? To address this question, various concentrations of 
either gClq-Kts or KLH-conjugated peptide were incubated 
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Figure  2.  Binding  of tzqgClq-g to Clq, and influence  of ionic strength or metal ions on binding. Binding  of radiohbeled  gClq-R to increasing 
concentrations of Clq was done in PB or PBS (150 raM NaC1) with or without 0.15 raM CaCI2 and 1 mM MgClv For comparison, the binding 
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Figure 3.  Solid  phase  binding  assay,  gadiohbded  gClq-g was incubated 
(2 h, 37~  with increasing  concentrations  of immobilized  Clq, cClq, 
gClq, or BSA in PBS, pH 7.5. After incubation, individual  walls were 
washed  five  times  and counted.  Each  data  point  represents a mean  of  three 
separate experiments run in quadruplicate. 
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with 10 #1 of NHS or GVB for I h at 37~  in a total volume 
of 100 t~g GVB. After incubation, the residual hemolytic ac- 
tivity was determined as described in Materials and Methods. 
Both the KLH-peptide and the gClq-Kts (data not shown) 
inhibited the hemolytic activity of  NHS. Neither KLH alone 
nor irrelevant  pepfides of similar length and charge as the 
gClq-Kts had such inhibitory activity. 
Anti.gCIq.R  and Antipeptide Antibodies Immunoblot a 33.kD 
Membrane Molecule+  Polyclonal antibodies raised against the 
33-kD molecule and its 18 amino acid-NH2-terminal pep- 
tide were used in immunoblotting studies. These results shown 
in Fig. 5 demonstrate that both antibodies recognize the same 
membrane molecule which migrates with an approximate mo- 
lecular mass  of 33 kD. 
CLSM Anal3nis Shows the 33.kD to Be Expressed on the Su~ace 
of  Man  7 Peripheral  Blood Cells.  To ascertain that gClq-R was 
a surface molecule, peripheral blood mononudear leukocytes 
were purified by Fieoll-Hypaque centrifugation as described d 
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Figm~ 4.  Binding  ofgClq-R to Clq andgClq 
is specific.  Microtiter  wells were  coated  with 500 
ng each of either Clq or gClq; 1,000 ng each 
of properdin, rabbit anti-cClq IgG, or a prein- 
cubated mixture of Clq (500 rig) and anti-cClq 
IgG (1,000 rig) to form  cClq-anti-cClq immune 
complex. After  washing  three  times  and blocking 
with 1% BSA-TBST, mIgClq-R was added, in- 
cubated (2 h, 37~  and analyzed  as described 
above. The mean  percent  binding  of three  experi- 
ments run in duplicate  is indicated  above  each  bar. 
in Materials and Methods and then analyzed by incubation 
with either IgG of preimmune rabbit,  anti-33-kD  IgG or 
antipeptide  IgG.  The bound  antibodies  were detected by 
incubation with FITC-conjugated P(ab')2 goat  anti-rabbit 
antibody. Approximately 90-95%  of the mononudear cell 
population  stained with various intensities with anti gClq-R 
antibodies. A  representative experiment (n  =  4) is shown 
in Fig. 6 and is presented as 0.5/~m optical sections of a rep- 
resentative stained cell 
Isolation of a eDNA  Clone Coding  for the Clq-binding Pro- 
tein.  Since the Clq-binding protein was isolated from the 
Raji call line, total RNA from Raji call was used as a tem- 
plate for first strand cDNA synthesis and subsequent PCR 
amplification, which employed primers BH-S and BH-3 (Table 
2). A DNA fragment of the expected size (66 bp) was gener- 
ated by PCR. This fragment was subdoned and three clones 
were sequenced. Based on the sequences,  two exact match 
primers (KS-1  and KA-1) were synthesized for use in the 
screening of a ), gt 11 library. Three positive clones were iso- 
lated from the human B cell library and all were found to 
contain the same cDNA sequence (Fig. 7). The longest clone 
was 1,139 bp long whereas the other two dones encompassed 
nucleotides 106-1113,  found in the longest clone. The de- 
rived amino acid sequence (Pig.  7) confirms the protein se- 
quencing data (amino acid sequence 74-97) and indicates that 
Figure 5.  Western blot analysis of Raji 
gClq-R. Solubilized  Raji  cell  membrane  pro- 
reins were analyzed by  SDS-PAGE and 
Western  blot  analysis  using anti-gClq-R  (lane 
I),  anti-peptide (lane 2),  and antipeptide 
preabsorbed with KLH-Sepharose  CL-4B 
(lane  3). A blot with rabbit IgG from  preim- 
mune  serum  was negative  (data not shown). 
the Clq-binding protein is synthesized as a pre-pro protein 
of 282 residues.  The mature protein which starts at residue 
74 is predicted from cDNA studies to be preceded by a 60 
residue-long hydrophobic stretch containing five cysteines. 
This in turn is predicted to be preceded by a 13 residue-long 
leader peptide (37).  The predicted molecular weight of the 
209 residue-long protein is 24.3 kD and contains three potential 
N-glycosylation sites at residues 114 (Asn-Gly-Thr), 136 (Ash- 
Ash-Set), and 223  (Asn-Tyr-Thr). 
Northern Blot Analysis.  Total RNA from various cell lines 
(38)  was analyzed and is shown in Fig. 8.  After stringent 
washing (0.1  x  SSC, 0.1% SDS, 65~  15 rain) and exposure 
for 7 d, strong signals were seen in both B ceU lines (Daudi 
and Raji,  Fig. 8), whereas weaker signals  could be seen in 
HepG2 and Molt-4 call lines.  No signal was seen in K562 
and only a smear could be seen in HL60. In another Northern 
blot carried out using the same conditions (data not shown), 
the U937 cell line (monocyte  cell line) yielded a weaker signal 
than the Raji cell line but a comparable signal to that ob- 
tained with HepG2  and Molt-4 cell lines.  The size of the 
mRNA for the Clq-binding protein is  -1.5-1.6  kb. 
RT-PCR.  Using primers BM-1 and KS-2, a PCR frag- 
ment of 468 bp should be generated from first strand cDNAs 
of positive cell lines. The PCR products were run into a 2% 
(wt/vol) NuSieve gel and the results are shown in Fig.  9. 
In the positive control, plasmid containing the Clq-binding 
protein cDNA was used as template in the PCR reaction, 
whereas there is no first strand cDNA template in the nega- 
tive control.  There are strong signals in HepG2,  Molt-4, 
Daudi, Raji, and U937 cells, but none in K562 cells. There 
is a weak signal from HL60, showing that it has a low level 
of the Clq-binding protein mRNA which is not detectable 
by Northern blotting. 
Production of Recombinant Protein and its Properties.  The 
1816  Receptor  for Globular "Heads" of Clq Figure  6.  Con.focal laser scanning microscopic 
imaging (CLSM). Mononuclear lenkocytes were 
incubated  (30  min,  37~  in  GVB  containing 
0.02% NaN5 with IgG preimmune rabbit serum, 
IgG anti=gClq-R, or anti-gClq-R peptide. The 
bound antibodies were detected by goat FITC-lgG 
anti-rabbit and analyzed by CLSM. Approximately 
90-95% of the cells stained with both antibodies. 
The image in the top panel (B) is a 0.5/~m section 
of a representative  cell stained with anti=gClq-R 
and (,4) is the transmitted light image of the sec= 
tion in (B), whereas  (C) represents  a composite 
image of (,4) and (B). The bottom panel is acom= 
posite of a series of 0.5-#m sections  taken from 
the center of the cell ("equator") upwards to the 
"pole" (top left to right and bottom left to right). 
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Figure  7.  eDNA and derived amino acid sequences of the Clq-binding 
protein. Nucleotide sequences are numbered (right) and amino add sequences 
are numbered (/eft). Amino acid residue number one is the first methio- 
glutathione-S-transferase  (GST)-gClq=R fusion protein was 
purified  as described  in Materials  and Methods on a GST 
affinity column followed by digestion of fusion protein with 
thrombin and passage over a Mono=Q column. The various 
stages in the purification procedures were assessed by 15% 
(wt/vol) SDS=PAGE and the major bands identified by NH2- 
terminal protein sequencing. The protein band identified by 
NH2-terminal  sequencing  to  be  glutathione-S=transferase, 
had a molecular mass  of 26 kD.  The protein band shown 
to be the Clq-binding protein, had an apparent molecular 
nine of the putative translated sequence. The derived amino acid sequence 
confirms the NHz-terminal protein sequencing data obtained from the ma- 
tare protein isolated from Raji cells (amino acid sequence residues 75-97, 
(underlined). (*) The stop codon tag at nucleotides 924-926; (double under- 
line) the three potential N-glycosylation  sites. These sequence data are avail- 
able from EMBL/GenBank/DDBJ  under accession number X75913. 
1817  Ghebrehiwet et al. Figure  8.  Northern blot analysis. Total RNA (10 ~g) from various cell 
lines were analyzed. The samples were HepG2 cells (lane I), Molt-4 cells 
(lane 2); K562 cells (lane 3); Daudi cells (lane 4), Raji cells (lane 5), blank 
(lane 6),  and Kb60 cells (lane 7). The 18S and 28S rRNA were taken 
as size markers.  The size of the signal is •1.55  b. 
mass of 27-28 kD on SDS-PAGE (even though the molecular 
weight calculated from the amino acid sequence is only 24.3 
kD). In gel filtration  studies using a Superose 12 column, 
the recombinant Clq-binding protein was eluted at a posi- 
tion corresponding to 97.2 kD which is consistent  with it 
being a tetramer of a 24.3-kD polypeptide chain. 
Recombinant gClq-R (rgClg-R) Inhibits Clq Hemolytic Ac- 
tivity.  The recombinant, sohble form of gClg-R generated 
by expression in E. coli  was used to see its effect on Clq hemo- 
lytic activity in serum by incubating various concentrations 
of the recombinant molecule with NHS as described above. 
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Fipn  10.  Inhibition  of serum  hemolytic  activity  by recombinant 
gClq-K (rsClq-R). Various concentrations  of rgClq-R were incubated 
with NHS as described in the legend to Fig. 5 and assessed for comple- 
ment inhibitory activity. 
As shown in Fig. 10, the rgClq-R was capable of inhibiting 
the hemolytic activity of Clq in serum in a dose-dependent 
manner. To verify the specificity of this inhibition, rgClq-R 
was first preincubated with Clq before  addition to  Clq- 
depleted serum. Whereas, addition of Clq preincubated with 
rgClq-R did not reconstitute the hemolytic activity of Clq- 
depleted serum, the addition of Clq alone did, suggesting 
that addition of rgClq-R to serum indeed prevents the binding 
of Clq to immune complexes (data not shown). The gClq-R 
molecule does not, however, activate complement as assessed 
by C4 titration (data not shown). 
Figure  9.  RT-PCR. Lanes 1 and 11 contain molecular weight standards. 
The samples are: HepG2 cells (lane 2); Molt-4 cells (lane 3); K562 cells 
(lane 4); Dandi cells (lane 5); Raji ceils (lane 6); U937 cells (lane 7); FIL60 
cells (lane 8); negative control (lane 9); and positive control (lane 10); respec- 
tively. A PCR fragment  of 468 bp could be seen in positive cell lines. 
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Discussion 
The existence of two distinct types of Clq receptors had 
been suggested earlier by Bordin et al. (6, 18) who showed 
that human diploid fibroblasts express a low a~nity Clq-R 
for the collagen-like domain and a small subpopulation  ex- 
pressing high affinity Clq-R which binds to the globular 
region of Clq. The present report describes the purification, 
functional characterization,  cDNA cloning, and overexpres- 
sion of this molecule henceforth referred to as the gClq-R. 
The gClq-R molecule was isolated to homogeneity using 
the same purification  procedures for cClq-R and employed 
a combination of two previously published methods (2, 28, 
32). Functional and immunochemical  characterization of the 
gClq-R molecule revealed that: (a) it is a unique protein that 
does not share cross-reactive  epitopes with cClq-R; (b) it binds 
with high affinity to the globular heads of Clq even when 
the collagen taft of Clq is saturated by anti-cClq IgG;  (c) 
both the purified and recombinant forms of the molecule in- 
of Clq hibit the hemolytic activity of Clq in serum and this inhibi- 
tory activity may reside within the 24 amino acid residues 
of the NHz terminus; and (d) anti-gClq-R antibodies blot 
a 33-kD molecule from Raji cells as well as other types of 
cells. Furthermore, CLSM analyses  of peripheral blood mono- 
cytes and lymphocytes (Fig. 6) and other blood cells (8) with 
anti gClq-R antibodies  show that gClq-R is expressed on 
the surface of these cells, although the degree of expression 
was found to differ from cell type to r  type. These results 
indicate that gClq-R is coexpressed with cClq-R and is likely 
to be ubiquitously distributed (1). 
The cDNA for the Clq-binding protein encodes a pre-pro 
protein of 282 residues, as determined from the first methio- 
nine, whereas NHz-terminal sequence of the mature protein 
isolated from Raji cell begins with residue 74 (Leu) (Fig. 7). 
It is uncertain if this is due to proteolytic cleavage during 
protein purification  or if this protein has an unusually long 
signal peptide of 73 residues. It seems probable that residues 
1-13,  or 1-7, form the signal peptide of the Clq-binding 
protein since they give scores of 5.5 and 4.5, respectively, 
in the SIGCLEAVE command of the GCG program (39). 
The mature protein (residues 74-282) is highly charged and 
is very acidic, with a calculated pI of 4.15. Out of 209 residues 
in the mature protein, there are 28 glutamic acid, 20 aspartic 
acid, 16 lysine, 5 histidine,  and 4 arginine residues. In con- 
trast,  the first 73 residue-long stretch of the pre-pro protein 
does not have any glutamic acid, aspartic acid, lysine, or histi- 
dine residues, but does have 11 arginine residues. The mature 
protein has only one cystine and thus should not have any 
intra-chain disulfide bonding. 
Since the mature protein contains many charged residues 
distributed all through the sequence, it is unlikely that it con- 
tains a transmembrane domain. Rather, the NHz-terminal 
73 residue-long stretch, which is too long for a signal pep- 
tide, is more likely to contain a transmembrane and a cyto- 
plasmic domain, in addition to a signal peptide. The mature 
protein purified from the Raji cell line has an apparent mo- 
lecular mass of 33 kD in SDS-PAGE, much bigger than the 
calculated molecular weight from the primary sequence (24 
kD). This could be explained partly by three potential N-gly- 
cosylation  sites and partly by its highly acidic nature.  For 
instance, although the recombinant protein has a calculated 
molecular mass of 24.3 kD and should be smaller than its 
fusion partner, ghtathione-S-transferase (26 kD), it had a larger 
apparent molecular weight ('~,27.5 kD) than GST. On the 
other hand, the recombinant protein behaved as a tetramer 
of the 24.3-kD polypeptide chain on gel filtration in nondis- 
sociating  conditions, i.e.,  as a protein of 97.2 kD. 
Northern blot studies and RT-PCIk showed that this pro- 
tein was expressed in a variety of different types of cell lines. 
Daudi and Raji cells, which are both B cell lines, express a 
higher amount of mRNA than the other cell lines. The pro- 
tein is also expressed  in the U937 (a monocyte ceU line), Molt-4 
(a T call line) and HepG2 cell lines (a hepatocyte cell line), 
but at a lower level than in the B cell lines. It was shown 
by RT-PCIL that HL-60 (a cell line derived from human 
promyelocytic leukemia,  which is able to differentiate into 
nentrophil)  expresses a low level of Clq-binding protein 
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mRNA which was not detected by the Northern blotting 
study.  However,  both  Northern  blotting  and  RT-PCR 
confirmed that there is no expression in K562 cell line (a cell 
line derived from human myelogenous leukaemia, which is 
highly undifferentiated  and of the granulocytic series). Fur- 
thermore, in previous studies (8, 19), Western blot analyses 
showed that this protein is also expressed on eosinophils and 
neutrophils.  On the other hand, a protein, apparently iden- 
tical to the Clq-binding protein described in this paper, has 
been purified from HeLa cell line (a fibroblast cell line), and 
was initially identified as being a pre-mRNA splicing factor, 
designated as p32 or SF2 (40, 41). However, the claims that 
it was a pre-mRNA splicing factor, were withdrawn by the 
same group in their subsequent paper (42). The cDNA clone 
encoding p32 (41) lacked the first 90 nucleotides seen at the 
5' end of the cDNA clone encoding the Clq-binding protein 
(Fig. 7) and, therefore, it was concluded that p32 lacked an 
initiating methionine and a signal peptide.  However, both 
these features are seen in the amino acid sequence predicted 
for the Clq-binding protein (Fig. 7) and are consistent with 
this protein being secreted from the cell and found on the 
cell membrane. 
Whether this novel molecule plays a primary or auxiliary 
role within the broad scheme of Clq-Clq-R  interaction 
cannot be ascertained from the present studies.  However, 
the existence of a multi-receptor system may explain in part 
the participation  of Clq-R in such a vast array of cellular 
responses. It is shown that gClq-R is able to bind to the 
globular heads of Clq, even when it is associated with the 
Clrz-Cls2 complex.  The binding of gClq-R to C1 com- 
plexes can inhibit the binding of C1 to IgM sensitized eryth- 
rocyte and thus block the lysis of the erythrocyte by com- 
plement. Of course, under in vivo conditions,  the relative 
ratio of gClq-R and C1 is not the same as in in vitro ex- 
periments and, it is possible that C1 is able to bind to im- 
mune complexes, activate complement, and cross-link  the 
immune complexes to the Clq-binding protein on effector 
cell surfaces, like B cell, T cell, monocytes, etc. The binding 
may result in various biological responses. That gClq-R par- 
ticipates in a variety of biological responses is evident from 
a number of experiments. Aggregated Clq-mediated phtelet 
activation which leads to the induction of Otlro/~3 integrins 
and expression of procoagcnlant activity (14) can be inhibited 
by either preincubation of the platelets with anti gClq-R 
antibody or, preexposure of the aggregated Clq with gClq- 
Rls (43). In addition, the gClq-R and cClq-R, both of 
which are expressed on eosinophils, have been shown recent- 
ly to mediate chemotaxis and chemokinesis (8). These results 
clearly demonstrate that both receptors alone or in conjunc- 
tion with other cell surface molecules are involved in various 
Clq-mediated cellular responses.  Since the Clq molecule 
is postulated  to circulate in plasma with its globular heads 
potentially  available for  binding,  it  is  not  clear  how  a 
gClq-R-bearing cell avoids binding to Clq. One possible 
hypothesis is that the conformational change of Clq followed 
by binding to cClg-R must take place before the gClq-R 
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